Ana Elísabet López-Sundh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana Elísabet López-Sundh has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jose Luis Hernandez
Department of Internal Medicine and Psychiatry, Hospital Universitario Marqués de Valdecilla-IDIVAL, Immunopathology Group, University of Cantabria, Santander, Spain
3 shared publications - Marcos Antonio González-López
Dermatology Department, Department of Medicine and Psychiatry, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain
3 shared publications C. Gómez-Fernández
Department of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Cantabria, Spain
2 shared publications- Cristina Baldeón
Hospital Universitario Marqués de Valdecilla
2 shared publications - Javier Gonzalo Ocejo-Vinyals
Servicio de Inmunología, Laboratorio de Histocompatibilidad, Hospital Universitario Marqués de Valdecilla IDIVAL Santander Spain
2 shared publications - Ricardo Blanco
Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
2 shared publications
Latest Publications
- Open Access
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Open AccessErdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.
- 26 October 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (1) , 253-258
Keratitis‐ichthyosis‐deafness syndrome with lethal p.Ala88Val variant and severe hypercalcemia
Keratitis‐ichthyosis‐deafness (KID) syndrome is a rare genetic disease caused by pathogenic variants in connexin 26 (gene GJB2), which is part of the transmembrane channels of the epithelia. Connexin 26 is expressed mainly in the cornea, the sensory epithelium of the inner ear, and in the skin keratinocytes, which are the three main target organs in KID syndrome. Approximately a dozen pathogenic variants have been described to date, including some lethal forms. Patients with lethal pathogenic variants present with severe symptoms from birth and die from sepsis during the first year of life. We present a premature female patient with KID syndrome carrying the lethal p.Ala88Val pathogenic variant in GJB2. In addition to the respiratory distress associated with this variant, our patient presented severe hypercalcemia of unexplained origin refractory to treatment. This abnormality has not been reported earlier in other patients with KID syndrome with the same variant.
- 26 October 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (1) , 253-258
Keratitis‐ichthyosis‐deafness syndrome with lethal p.Ala88Val variant and severe hypercalcemia
Keratitis‐ichthyosis‐deafness (KID) syndrome is a rare genetic disease caused by pathogenic variants in connexin 26 (gene GJB2), which is part of the transmembrane channels of the epithelia. Connexin 26 is expressed mainly in the cornea, the sensory epithelium of the inner ear, and in the skin keratinocytes, which are the three main target organs in KID syndrome. Approximately a dozen pathogenic variants have been described to date, including some lethal forms. Patients with lethal pathogenic variants present with severe symptoms from birth and die from sepsis during the first year of life. We present a premature female patient with KID syndrome carrying the lethal p.Ala88Val pathogenic variant in GJB2. In addition to the respiratory distress associated with this variant, our patient presented severe hypercalcemia of unexplained origin refractory to treatment. This abnormality has not been reported earlier in other patients with KID syndrome with the same variant.
- Open Access
- 1 September 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (9) , 1505-1507
Neonatal scabies in times of confinement: An unexpected guest to be recognised
- 1 September 2021
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (9) , 1505-1507
Open AccessNeonatal scabies in times of confinement: An unexpected guest to be recognised
- 24 February 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 25 (3) , 342-343
Reader Comment Regarding “Approach to Chilblains During the COVID-19 Pandemic”
- 24 February 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 25 (3) , 342-343
Reader Comment Regarding “Approach to Chilblains During the COVID-19 Pandemic”
- 26 November 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (7) , 2985-2989
Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review
Calcinosis cutis (CC) is defined as the deposition of calcium salts on the skin and subcutaneous tissue. It is associated with different conditions, including some autoimmune diseases, and it can generate significant inflammation, pain, and functional impairment. Different therapies have been tried with limited results. Intralesional sodium thiosulfate seems a promising therapeutic option. We report a patient with diffuse systemic sclerosis who presented with two symmetrical plaques on both axillae, which caused pain and skin retraction. The clinical diagnosis was consistent with CC, which was confirmed by skin biopsy and ultrasound. The patient was treated with a 250 mg/ml solution of sodium thiosulfate injected into the plaques. Complete resolution was achieved after three monthly sessions. The only reported adverse effect was a transient burning sensation during the injections. Given its effectiveness and safety, we believe that intralesional sodium thiosulfate could become a valid first-line option for the treatment of CC.
- 26 November 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (7) , 2985-2989
Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review
Calcinosis cutis (CC) is defined as the deposition of calcium salts on the skin and subcutaneous tissue. It is associated with different conditions, including some autoimmune diseases, and it can generate significant inflammation, pain, and functional impairment. Different therapies have been tried with limited results. Intralesional sodium thiosulfate seems a promising therapeutic option. We report a patient with diffuse systemic sclerosis who presented with two symmetrical plaques on both axillae, which caused pain and skin retraction. The clinical diagnosis was consistent with CC, which was confirmed by skin biopsy and ultrasound. The patient was treated with a 250 mg/ml solution of sodium thiosulfate injected into the plaques. Complete resolution was achieved after three monthly sessions. The only reported adverse effect was a transient burning sensation during the injections. Given its effectiveness and safety, we believe that intralesional sodium thiosulfate could become a valid first-line option for the treatment of CC.
- Open Access
- 29 August 2020
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 19 (1) , 1-6
Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with several comorbidities and vascular risk factors, such as dyslipidemia. The present study aimed to assess the possible associations between the lipid profile and atherogenic indexes and the severity of HS. Methods: This case-control study enrolled 78 HS patients and 62 healthy controls. Classic lipid profile and lipoprotein ratios, including the atherogenic index of plasma (AIP), were evaluated. The severity of HS was measured by the HS Physician Global Assessment (PGA). Results: HS-patients had lower serum total cholesterol and HDL-C levels and higher AIP than the control group. AIP was positively correlated to BMI, waist circumference, systolic and diastolic blood pressure, LDL-C, triglycerides, non-HDL-C, ApoB, HOMA, and hs-CRP and negatively to HDL-C and ApoA1. For the overall lipid profile, only AIP was related to a more severe HS (PGA ≥ 3) after controlling for age, sex, BMI, insulin resistance (IR), active smoking, and statin use (r = 0.268; p = 0.023). Multiple logistic regression adjusted for age, sex, BMI, IR, smoking status and statin use, showed that AIP ≥ 0.11 was significantly associated with the severity of HS (OR, 4.38; CI 95%, 1.09–17.50; p = 0.037). Conclusions: In conclusion, these results showed that AIP is significantly and independently associated with HS severity.
- 29 August 2020
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 19 (1) , 1-6
Open AccessAtherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with several comorbidities and vascular risk factors, such as dyslipidemia. The present study aimed to assess the possible associations between the lipid profile and atherogenic indexes and the severity of HS. Methods: This case-control study enrolled 78 HS patients and 62 healthy controls. Classic lipid profile and lipoprotein ratios, including the atherogenic index of plasma (AIP), were evaluated. The severity of HS was measured by the HS Physician Global Assessment (PGA). Results: HS-patients had lower serum total cholesterol and HDL-C levels and higher AIP than the control group. AIP was positively correlated to BMI, waist circumference, systolic and diastolic blood pressure, LDL-C, triglycerides, non-HDL-C, ApoB, HOMA, and hs-CRP and negatively to HDL-C and ApoA1. For the overall lipid profile, only AIP was related to a more severe HS (PGA ≥ 3) after controlling for age, sex, BMI, insulin resistance (IR), active smoking, and statin use (r = 0.268; p = 0.023). Multiple logistic regression adjusted for age, sex, BMI, IR, smoking status and statin use, showed that AIP ≥ 0.11 was significantly associated with the severity of HS (OR, 4.38; CI 95%, 1.09–17.50; p = 0.037). Conclusions: In conclusion, these results showed that AIP is significantly and independently associated with HS severity.
- Open Access
- 27 August 2020
- Published by Springer Nature in Research Square
Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study
Background. Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with several comorbidities and vascular risk factors, such as dyslipidemia. The present study aimed to assess the possible associations between the lipid profile and atherogenic indexes and the severity of HS. Methods . This case-control study enrolled 78 HS patients and 62 healthy controls. Classic lipid profile and lipoprotein ratios, including the atherogenic index of plasma (AIP), were evaluated. The severity of HS was measured by the HS Physician Global Assessment (PGA). Results . HS-patients had lower serum total cholesterol and HDL-C levels and higher AIP than the control group. AIP was positively correlated to BMI, waist circumference, systolic and diastolic blood pressure, LDL-C, triglycerides, non-HDL-C, ApoB, HOMA, and hs-CRP and negatively to HDL-C and ApoA1. For the overall lipid profile, only AIP was related to a more severe HS (PGA≥3) after controlling for age, sex, BMI, insulin resistance (IR), active smoking, and statin use (r=0.268; p=0.023). Multiple logistic regression adjusted for age, sex, BMI, IR, smoking status and statin use, showed that AIP≥0.11 was significantly associated with the severity of HS (OR, 4.38; CI 95%, 1.09-17.50; p=0.037). Conclusions . In conclusion, these results showed that AIP is significantly and independently associated with HS severity.
- 27 August 2020
- Published by Springer Nature in Research Square
Open AccessAtherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study
Background. Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with several comorbidities and vascular risk factors, such as dyslipidemia. The present study aimed to assess the possible associations between the lipid profile and atherogenic indexes and the severity of HS. Methods . This case-control study enrolled 78 HS patients and 62 healthy controls. Classic lipid profile and lipoprotein ratios, including the atherogenic index of plasma (AIP), were evaluated. The severity of HS was measured by the HS Physician Global Assessment (PGA). Results . HS-patients had lower serum total cholesterol and HDL-C levels and higher AIP than the control group. AIP was positively correlated to BMI, waist circumference, systolic and diastolic blood pressure, LDL-C, triglycerides, non-HDL-C, ApoB, HOMA, and hs-CRP and negatively to HDL-C and ApoA1. For the overall lipid profile, only AIP was related to a more severe HS (PGA≥3) after controlling for age, sex, BMI, insulin resistance (IR), active smoking, and statin use (r=0.268; p=0.023). Multiple logistic regression adjusted for age, sex, BMI, IR, smoking status and statin use, showed that AIP≥0.11 was significantly associated with the severity of HS (OR, 4.38; CI 95%, 1.09-17.50; p=0.037). Conclusions . In conclusion, these results showed that AIP is significantly and independently associated with HS severity.